Journal
TUMORI JOURNAL
Volume -, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/03008916231202149
Keywords
Molecular oncology; target therapy; thoracic oncology; ALK inhibitors; molecular resistance
Categories
Ask authors/readers for more resources
ALK is a potent oncogenic driver of lung adenocarcinoma and can be targeted with drugs to improve patient outcomes. However, resistance mechanisms limit the durability of the therapeutic effects. New therapeutic strategies are being investigated to overcome this resistance.
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK-rearranged LUADs when used as first- or second-line agents. However, resistance mechanisms greatly limit the durability of the therapeutic effects elicited by these TKIs. The molecular mechanisms responsible for these resistance mechanisms have been in part elucidated, but overcoming acquired resistance to ALK-derived therapy remains a great challenge. Some new therapeutic strategies under investigation aim to induce long-term remission in ALK-fusion positive LUADs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available